Fibrovein 3% (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 279 | Huge venous malformation with cervical, oral and pharyngeal diffuse lesion | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-001455-37-NO (EUCTR) | 21/12/2011 | 01/06/2011 | Prospective randomized interventional study in patients with venous malformations. | Prospective randomized interventional study. Compare the effect of bleomycin and Tetradecyl Sodium Sulphate (Fibrovein) in the treatment of venous malformations. Clinical neurological and neurophysiological study of a subpopulation of patients with venous malformations. | Venous malformation MedDRA version: 13.1;Level: LLT;Classification code 10047229;Term: Venous malformation NOS;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Bleomycin Baxter Product Name: Bleomycin Trade Name: Fibrovein 3% Product Name: Fibrovein 3% | Department of Radiology, Oslo University Hospital, Norway | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Norway |